PA-PCI-PHARMA-SERVICES
12.10.2021 15:27:09 CEST | Business Wire | Press release
PCI Pharma Services (PCI) , a leading pharmaceutical and biopharmaceutical global integrated solutions provider, announced it has signed a definitive agreement to acquire Lyophilization Services of New England, Inc. (LSNE), a premier contract development and manufacturing organization (CDMO) headquartered in Bedford, New Hampshire, from global private equity firm Permira . Founded in 1997, LSNE has an impressive history of serving global pharmaceutical, biotechnology and medical device companies, differentiated by its high-quality cGMP aseptic fill-finish capabilities, and expertise in and ability to scale lyophilization, an important manufacturing process commonly used with injectable and biologic therapies. LSNE will expand PCI’s breadth of services as a global CDMO, building on PCI’s expertise in biologics packaging and specialty manufacturing. The acquisition adds five FDA-approved facilities in the U.S. (New Hampshire, Wisconsin) and Europe (Spain), with a sixth expecting approval over the coming months, and three additional facilities under development, to strengthen PCI’s global 30-site network.
“We are excited to welcome LSNE into the PCI family,” said Salim Haffar, chief executive officer, PCI Pharma Services. “Their passion for patients, talented team, robust compliance culture, operating excellence and innovative approach to client challenges are perfectly aligned with our global strategy as PCI strives to be the bridge between life-changing therapies and patients around the world. We are particularly eager to note that this acquisition will expand our manufacturing offerings worldwide, providing clients with a single source for their drug development and packaging needs, reducing supply chain complexity and accelerating speed to market for their much-needed treatments.”
With the addition of LSNE, PCI will be able to offer integrated large and small molecule solutions for its clinical and commercial clients. This includes expanded global manufacturing capabilities in complex formulations, high potency, and now lyophilization for a broad range of injectables including nanoparticles, mRNA, mABs, proteins, oligonucleotides, and other biologics across formats from vials and bottles to pre-filled syringes and autoinjectors.
“We are delighted that LSNE is joining the PCI team and anticipate a seamless integration for our employees and clients. We have a shared focus on innovation, quality, exceptional customer service and our people,” said Matt Halvorsen, LSNE founder and CEO. “Joining forces with a global industry leader, such as PCI, is a great step forward for LSNE and will produce a winning combination for our clients, employees and the patients we jointly serve.”
LSNE marks PCI’s fourth acquisition in three years, exemplifying PCI’s enhanced focus on global specialty manufacturing capabilities while complementing its existing clinical and commercial packaging expertise. Matt Jennings, PCI Chairman, added, “On behalf of our investors we are delighted to support this strategic and transformational investment to create a top-tier global and integrated CDMO benefitting patients, clients, employees and shareholders. This milestone underscores PCI’s global strategy and commitment to be the partner of choice for specialized client needs.”
Jefferies LLC acted as exclusive financial advisor and Paul, Weiss, Rifkind, Wharton & Garrison LLP as counsel to PCI Pharma Services.
PCI is headquartered in Philadelphia, PA.
About PCI Pharma Services
The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. Leading technology and continued investment enable us to address global development needs throughout the product life cycle — from Phase I Clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pciservices.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005721/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa Expands Commercial Solutions Hub with Integration of Visa Accounts Receivable Manager27.5.2026 14:00:00 CEST | Press release
New integration allows issuers to send virtual card details to suppliers, helping automate virtual card adoption for suppliers at scale Visa Inc. (NYSE: V), a global leader in digital payments, today announced an expansion of the Visa Commercial Solutions Hub (VCS Hub), further strengthening how issuers and suppliers connect to scale virtual card programs. Through a new integration with Visa Accounts Receivable Manager (Visa AR Manager), eligible issuers gain built-in access to end-to-end processing designed to reduce operational friction and accelerate commercial card growth. Virtual cards are among the fastest-growing payment methods in commercial payments yet scaling them remains complex. Issuers often face fragmented supplier connectivity, while suppliers are left with manual reconciliation and inconsistent payment flows. By bringing issuer and supplier networks together, by embedding access to Visa AR Manager in the VCS Hub, Visa is helping to simplify these connections and enable
Parse Biosciences and bit.bio Announce Landmark Alliance27.5.2026 14:00:00 CEST | Press release
Unlocking Cell Fate: Alliance will power AI-driven predictive medicine and human cell manufacturing Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced an alliance with bit.bio to create a comprehensive map of transcription factor-driven cell identity, encompassing both cell state and cell fate. This map will serve as the foundational blueprint for developing highly accurate, human-relevant models at scale. By precisely mimicking in vivo biological responses, these models will significantly advance predictive drug discovery and therapeutic development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527668821/en/ The alliance will leverage cutting-edge techniques in massively parallel causal transcriptomics, which allows scientists to test thousands of genetic variables simultaneously to understand what drives cell behavior. bit.bio will contribute its indust
Echodyne Expands Public Safety Radar Applications Through Partnership with Axon27.5.2026 14:00:00 CEST | Press release
Partnership supports safer and more scalable drone operations across law enforcement, homeland security, and Drone as First Responder programs globally Echodyne, the radar platform company, today announced a partnership with Axon (Nasdaq: AXON), the global public safety technology leader, to support a joint focus activity on delivering best in class infrastructure for a range of homeland security and law enforcement UAS applications in the U.S and globally. Under the partnership, Echodyne’s advanced radar technology will continue supporting Axon’s growing ecosystem of public safety drone solutions, enhancing low-altitude airspace awareness for authorized drone operations while helping agencies detect and respond to unauthorized or malicious drone activity. There is increasing demand globally for comprehensive detailed awareness of the low altitude airspace in which drones are proliferating. Drone as First Responder (DFR) operations can deliver critical information to public safety agen
ENGIE and NHOA Energy Break Ground on 320MWh Drogenbos Battery Project in Belgium27.5.2026 13:22:00 CEST | Press release
Construction officially underway, marking a key milestone in the delivery of one of the largest battery storage systems in Benelux NHOA Energy, global provider of utility-scale energy storage systems, joined ENGIE today in marking a significant milestone with the groundbreaking ceremony of a 320MWh Battery Energy Storage System (BESS) at ENGIE’s Drogenbos power station, near Brussels. The ceremony, held this morning in the presence of Hans Bonte, Minister of Energy of the Government of Flanders, Vincent Verbeke, CEO of ENGIE Belgium, Nicolas van den Abeele, Managing Director Renewables & Batteries Benelux of ENGIE, and Giuseppe Artizzu, CEO of NHOA Energy, marked the official start of construction of ENGIE’s third large-scale battery project in Belgium. Awarded under Belgium’s fifth Capacity Remuneration Mechanism (CRM) auction, the project will contribute to the adequacy of the national electricity system under a 15-year contract starting in November 2027. ENGIE has entrusted NHOA Ene
NIQ Launches Survey Groups to Connect Consumer Sentiment with Real Purchase Behavior27.5.2026 13:00:00 CEST | Press release
New integrated capability connects consumer sentiment with real-world purchase data, enabling more confident, action‑driven decisions NIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of Survey Groups in NIQ Discover, a new capability that enables brands and retailers to understand not just what is changing in the market, but why. Available immediately within NIQ Discover, Survey Groups build on NIQ Panel Surveys by linking attitudinal insights to real-world purchase behavior from NIQ’s consumer panels—helping clients uncover the motivations behind performance shifts, identify opportunity gaps, and act with greater confidence in an increasingly complex consumer landscape. What’s New: Survey Groups in Discover Survey Groups make NIQ Panel Survey insights easier to access, analyze, and activate within existing workflows. By grouping survey responses with purchase behavior, clients can: Analyze key consumer segments with greater precision Understand the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom